MGLN · Magellan Health Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $546.34M | $520.51M | $492.37M | - | $560.27M | $528.07M | $486.14M | - | $482.28M | $461.19M |
| Gross Profit | $37.98M | $32.30M | $75.12M | - | $45.63M | $53.60M | $74.85M | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $23.67M | $22.52M | $21.42M | - | $24.73M | $23.89M | $28.68M | - | $34.16M | $33.49M |
| Operating Income | $747.0K | $10.78M | $39.41M | - | ($19.63M) | $10.78M | $34.84M | - | $29.14M | $21.22M |
| Interest Expense | $5.97M | $6.23M | $6.43M | - | $7.29M | $8.00M | $9.03M | - | $9.01M | $9.14M |
| Income Tax | $861.0K | ($1.20M) | $10.90M | - | ($2.33M) | ($36.33M) | $16.59M | - | $7.87M | $7.61M |
| Net Income | $5.94M | ($666.0K) | $27.83M | - | $11.65M | $83.50M | $18.25M | - | $21.27M | $13.61M |
| EPS - Basic | $0.03 | ($0.03) | $1.07 | - | $0.46 | $3.33 | $0.74 | - | $0.87 | $0.56 |
| EPS - Diluted | $0.03 | ($0.03) | $1.04 | - | $0.46 | $3.30 | $0.73 | - | $0.86 | $0.56 |
Balance Sheet
| Line item | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $678.51M | $456.31M | $1.14B | $152.05M | $160.42M | $383.96M | $325.25M | $376.70M | $260.35M |
| Accounts Receivable | $827.17M | $827.00M | $793.50M | $743.50M | $769.16M | $753.07M | $923.72M | $890.07M | $812.74M | $810.43M |
| Inventory | $39.83M | $38.79M | $46.39M | $43.33M | $37.64M | $36.69M | $42.33M | $44.96M | $48.37M | $45.61M |
| Accounts Payable | $171.77M | $132.30M | $149.76M | $137.38M | $122.02M | $99.20M | $104.36M | $88.42M | $92.36M | $75.44M |
| Current Assets | $2.20B | $2.02B | $2.02B | $2.16B | $2.29B | $2.25B | $1.81B | $1.67B | $1.66B | $1.58B |
| Total Assets | $3.35B | $3.22B | $3.24B | $3.36B | $3.38B | $3.35B | $3.22B | $3.09B | $3.14B | $3.08B |
| Current Liabilities | $756.02M | $629.63M | $662.21M | $737.58M | $1.10B | $1.10B | $1.03B | $910.15M | $978.42M | $925.13M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.38B | $1.26B | $1.29B | $1.46B | $1.80B | $1.81B | $1.79B | $1.69B | $1.78B | $1.74B |
| Stockholders' Equity | $1.93B | $1.92B | $1.91B | $1.87B | $1.58B | $1.54B | $1.43B | $1.40B | $1.33B | $1.32B |
| Retained Earnings | $1.89B | $1.88B | $1.88B | $1.86B | $1.59B | $1.58B | $1.49B | $1.48B | $1.45B | $1.43B |
Cash Flow
| Line item | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($77.88M) | - | - | - | $31.73M | - | - | - |
| Investing Cash Flow | - | - | ($509.46M) | - | - | - | ($28.00M) | - | - | - |
| Financing Cash Flow | - | - | ($100.80M) | - | - | - | $54.99M | - | - | - |
| CapEx | - | - | $19.54M | - | - | - | $15.72M | - | - | - |
| Free Cash Flow | - | - | ($97.42M) | - | - | - | $16.01M | - | - | - |
Ratios
| Metric | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 | Q2 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | -3.50 | - | - | - | 0.88 | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | 12.7% | - | 28.2% | - | -25.0% | -77.0% | 47.6% | - | 27.0% | 35.8% |
| Return on assets | 0.2% | -0.0% | 0.9% | - | 0.3% | 2.5% | 0.6% | - | 0.7% | 0.4% |
| Return on equity | 0.3% | -0.0% | 1.5% | - | 0.7% | 5.4% | 1.3% | - | 1.6% | 1.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.92 | 3.20 | 3.06 | 2.92 | 2.08 | 2.05 | 1.75 | 1.84 | 1.70 | 1.71 |
| Quick ratio | 2.86 | 3.14 | 2.99 | 2.86 | 2.05 | 2.02 | 1.71 | 1.79 | 1.65 | 1.66 |
| Cash ratio | 1.37 | 1.08 | 0.69 | 1.55 | 0.14 | 0.15 | 0.37 | 0.36 | 0.39 | 0.28 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 0.1x | 1.7x | 6.1x | - | -2.7x | 1.3x | 3.9x | - | 3.2x | 2.3x |
| Equity multiplier | 1.73 | 1.67 | 1.69 | 1.80 | 2.14 | 2.17 | 2.25 | 2.21 | 2.36 | 2.33 |
| Liabilities / Assets | 0.41 | 0.39 | 0.40 | 0.43 | 0.53 | 0.54 | 0.56 | 0.55 | 0.57 | 0.57 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 13.72 | 13.42 | 10.61 | - | 14.89 | 14.39 | 11.48 | - | 9.97 | 10.11 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 27d | 27d | 34d | - | 25d | 25d | 32d | - | 37d | 36d |
| Days payable outstanding | 115d | 93d | 111d | - | 79d | 69d | 78d | - | 70d | 60d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -16.8% | -39.7% | 0.4% | - | - | - | -94.0% | - | - | - |
| Operating income growth (YoY) | - | 0.0% | 13.1% | - | - | -49.2% | 3491.5% | - | -28.9% | 15.5% |
| Net income growth (YoY) | -49.0% | - | 52.5% | - | -45.3% | 513.4% | 4134.3% | - | -21.6% | 0.5% |
| EPS growth (YoY) | -93.5% | - | 42.5% | - | -46.5% | 489.3% | 3550.0% | - | -21.1% | 5.7% |
| EPS CAGR (3y) | -69.8% | - | 32.2% | - | -29.6% | 143.0% | -0.5% | - | -6.7% | 51.8% |
| EPS CAGR (5y) | -51.0% | - | 14.0% | - | - | 81.0% | 21.1% | - | -3.0% | 25.5% |
| FCF growth (YoY) | - | - | - | - | - | - | -29.7% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | -6.8% | - | - | - |
| Book value growth (YoY) | 22.5% | 24.7% | 33.4% | 33.8% | 18.6% | 17.0% | 9.7% | 8.8% | 0.0% | 0.0% |
Peer comparison
Same SIC group: Services-Hospitals
Comparing MAGELLAN HEALTH INC against the 3 most active filers in the same SIC group.